Paclitaxel poliglumex

Drug Profile

Paclitaxel poliglumex

Alternative Names: CHC 12103; CT-2103; Opaxio; PG - paclitaxel CTI BioPharma; PG-TXL; Poly(L-glutamic acid)-paclitaxel conjugate; Polyglutamate - Taxol; Polyglutamate-paclitaxel conjugate; Polyglutamic acid paclitaxel; PPX; Xyotax™

Latest Information Update: 11 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PG-TXL Company; University of Texas M. D. Anderson Cancer Center
  • Developer Brown University; CTI BioPharma; Gynecologic Oncology Group; National Cancer Institute (USA); State University of New York
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Taxanes
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Glioblastoma; Glioma
  • Phase I/II Head and neck cancer
  • No development reported Non-small cell lung cancer; Oesophageal cancer
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 May 2015 Phase-III is ongoing for Fallopiam tube cancer, ovarian cancer, peritoneal cancer; phase-II for glioblastoma/glioma; phase-I/II for head and neck cancer in USA
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top